Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine - Biologic Drug Details

Summary for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine

Recent Clinical Trials for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1

See all diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi Pasteur Limited	PENTACEL	diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine	Injection	125145	6,696,065	2016-07-02	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	PENTACEL	diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine	Injection	125145	8,551,451	2029-10-23	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	PENTACEL	diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine	Injection	125145	8,623,380	2024-05-04	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine

Country	Patent Number	Estimated Expiration
Argentina	073959
Brazil	PI0920630
Canada	2741396

Market Overview & Key Trends

Last updated: February 17, 2026

The vaccine combination product containing diphtheria, tetanus toxoids, and acellular pertussis (DTaP), inactivated poliovirus (IPV), and Haemophilus influenzae type b (Hib) conjugate (tetanus toxoid conjugate) targets a broad spectrum of childhood immunizations. The market for combination vaccines is expanding due to increasing immunization coverage, rising awareness of vaccine benefits, and efforts to reduce vaccination visits. Major players include Sanofi, GlaxoSmithKline (GSK), Merck, and Sinopharm.

Market Size and Growth Rate

As of 2022, the global pediatric combination vaccine market was valued at approximately $8 billion, with an expected compound annual growth rate (CAGR) of 8-10% through 2027. The growth stems from immunization programs expanding in emerging markets and developed regions gradually replacing standalone vaccines.

Year	Estimated Market Value (USD billion)	CAGR (2022-2027)
2022	8.0	8-10%
2023	8.7
2024	9.4
2025	10.2
2026	11.2
2027	12.2

Key Market Drivers

• Regulatory push toward combination vaccines due to improved compliance and coverage.
• Increasing vaccination initiatives in Asia-Pacific, Africa, and Latin America.
• Stability advantages, simplifying logistics, and reducing healthcare visits.
• Rising adult booster needs, though the primary market remains pediatric.

Regulatory and R&D Dynamics

Approval pathways favor combination vaccines to streamline immunization schedules. Recent approvals include updates in the US FDA and EMA for vaccines containing IPV components aligned with new CDC guidelines. Biotech firms focus R&D resources on improving immunogenicity, thermostability, and reducing adverse events.

Competitive Landscape & Patent Considerations

Patent protections for key adjuvants and conjugates influence market entry. Merck’s Pentacel (DTaP/IPV/Hib) is a leading combination vaccine. Companies pursuing biosimilar or next-gen conjugate formulations face patent cliffs and proprietary adjuvant restrictions. Patent expirations for older formulations are expected from 2025 onwards, opening opportunities for biosimilars.

Pricing & Reimbursement

Pricing varies globally, influenced by healthcare policies and procurement volumes. Developed markets report vaccine prices between $15–$50 per dose. Emerging markets benefit from GAVI support and lower price thresholds, expanding access but constraining margins for manufacturers.

Risks & Challenges

• Regulatory delays in developing regions.
• Vaccine hesitancy impacting uptake.
• Supply chain disruptions affecting manufacturing precision.
• Scientific challenges in combining multiple antigens without compromising immunogenicity.

---

Financial Trajectory & Investment Outlook

Revenue Growth Prospect

Major manufacturers project steady growth aligned with global immunization efforts. For example, Sanofi’s pediatric vaccines division anticipates a compound annual revenue increase of 7-9% for combination vaccines over the next five years. The drivers include production expansions, new licensures in underserved markets, and emerging adult booster programs.

R&D and Innovation Spend

Biotech firms invest heavily in novel conjugate linkers, thermostable formulations, and adjuvant optimization. Reported R&D budgets for leading vaccine firms range from 15-25% of annual revenues, reflecting a focus on improving existing vaccines and developing next-generation products.

Market Risks Impacting Investment

• Potential for regulatory setbacks delaying product launches.
• Patent expiries exposing markets to biosimilar competition.
• Changing immunization schedules reducing demand for existing formulations.
• Political and economic instability affecting procurement programs.

Forecasted Margins & Profitability

Profit margins for combination vaccine products hover around 50-60%. Cost pressures from ingredients, manufacturing, and distribution influence profitability. Price negotiations and subsidies in low-income countries reshape revenue streams.

---

Key Takeaways

• The global market for DTPa, IPV, Hib conjugate vaccines is forecasted to grow at 8-10% annually through 2027.
• Manufacturers are investing in next-generation formulations that improve efficacy, stability, and logistics.
• Patent expiries beginning around 2025 pose competitive threats but also open market fractions for biosimilar entry.
• Pricing varies significantly across regions, with developed markets maintaining higher margins.
• Risks include regulatory delays, vaccine hesitancy, and supply chain logistics challenges.

---

FAQs

1. What are the primary growth drivers for combined diphtheria, tetanus, pertussis, poliovirus, and Hib vaccines?
Increasing immunization coverage, vaccine mandates, and efforts to streamline administration schedules drive growth in combination vaccines.

2. How do patent expirations influence the market for these vaccines?
Patent expirations from 2025 onward open opportunities for biosimilar manufacturers, increasing competition and potentially reducing prices.

3. What technological innovations are anticipated to impact this vaccine segment?
Development of thermostable formulations, novel conjugation techniques, and adjuvants is expected to improve immunogenicity and logistics.

4. Which regions present the largest growth opportunities?
Asia-Pacific, Latin America, and African markets will see the fastest expansion due to increasing vaccination programs and economic growth.

5. What are the main risks for investors in this vaccine market segment?
Regulatory delays, changing immunization guidelines, vaccine hesitancy, and supply chain disruptions pose key risks.

---

Sources:

[1] MarketsandMarkets, “Vaccine Market by Type, Design, Application, and Region- Global Forecast to 2027,” 2022.
[2] EvaluatePharma, “Vaccine Industry Market Outlook,” 2023.
[3] WHO, “Global Vaccine Market Report,” 2022.
[4] CDC, “Immunization Schedules and Recommendations,” 2023.
[5] industry reports, “Biotech Innovations in Vaccine Conjugates,” 2023.